Vnitr Lek 2020, 66(5):e38-e42 | DOI: 10.36290/vnl.2020.096

An incidental finding of pheochromocytoma in a 33-year-old patient with Lynch syndrome

Emília Mojtová1, Jana Hanajíková2, Olívia Hamidová3, Gabriel Bognár4, Daniel Dyttert5, Marianna Grigerová1, Štefan Kečkéš6, Ján Podoba1
1 Klinika endokrinológie LF SZU a OUSA, Bratislava
2 II. rádiologická klinika LF UK a OUSA, Bratislava
3 Klinika lekárskej genetiky, OUSA Bratislava
4 Ústav patológie LF SZU a OUSA, Bratislava
5 Klinika onkologickej chirurgie LF UK a OUSA, Bratislava
6 Oddelenie imunodiagnostiky OUSA a Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, Bratislava

Pheochromocytoma is a catecholamine-producing neuroendocrine tumor arising from chromaffin cells of the adrenal medulla. The detection of these tumors is extremely important because they are associated with high cardiovascular morbidity and mortality. Progress in molecular genetics has revealed that up to 35% of pheochromocytomas are inhereted. Lynch syndrome (hereditary nonpolypous colorectal cancer - HNPCC) is an autosomal dominant genetic condition that is associated with a high risk of colorectal cancer or other extracolonic tumors (adenocarcinoma of endometrium, stomach, ovarian carcinoma, carcinoma of urinary tract, small intestine, brain tumors and skin cancer). Foreign medical journals are reporting an increasing number of cases on coexistence of HNPCC and neuroendocrine tumors, including pheochromocytoma. It increases the likelihood that this type of tumor could represent an additional extracolonic manifestation of Lynch syndrome.

Keywords: pheochromocytoma, Lynch syndrome, extracolonic manifestation.

Published: August 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mojtová E, Hanajíková J, Hamidová O, Bognár G, Dyttert D, Grigerová M, et al.. An incidental finding of pheochromocytoma in a 33-year-old patient with Lynch syndrome. Vnitr Lek. 2020;66(5):e38-42. doi: 10.36290/vnl.2020.096.
Download citation

References

  1. Zelinka T, Widimský J. Pheochromocytoma - Why is its early diagnosis so important for patient? | Feochromocytom - Proč je jeho časná diagnóza pro pacienta dôležitá? Vnitř Lék., 2015; 61 (5) : 487-491.
  2. Pacák K, Lazúrová I. Endokrinní nádory nadledvin v současné klinické praxi. Galen; 2011: 240 s.
  3. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology, 34, 2005; 34: 8812-8818. Go to original source... Go to PubMed...
  4. Martucci VL, Pacak K. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, Management and Treatment. Curr Probl Cancer, 2014; 38: 7-41. Go to original source... Go to PubMed...
  5. Jochmanova I, Wolf KI, King KS, et al. SDHB‑related pheochromocytoma and paraganglioma penetrance and genotype‑phenotype correletions. J Cancer Res Clin Oncol, 2017; 143: 1421-1435. Go to original source... Go to PubMed...
  6. Costa MHS, Ortiga‑Carvalho TM, Violante AD, et al. Pheochromocytomas and paragangliomas: clinical and genetic approach. Frontiers in Endocrinology. 2015, 6: 1-9. Go to original source... Go to PubMed...
  7. Lenders JWM, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet 2005; 366: 665-675. Go to original source... Go to PubMed...
  8. Jochmanová I, Lazúrová I. Diagnostika a manažment metastatického feochromocytómu a paragangliómu. Vnitř Lék, 2017; 63(9): 580-588. Go to original source... Go to PubMed...
  9. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2014; 99: 1915-1942. Go to original source... Go to PubMed...
  10. Závodná K, Vávrová Ľ, Hamidová O. Diagnostika pacientov s Lynchovým syndrómom. Onkológia, 2017; 12(6): 414-420.
  11. Ilenčíková D, Bartošová Z, Babál P. Lynchov syndróm - novinky v diagnostike a liečbe. Onkológia, 2010; 5 (2): 70-77.
  12. Perrier RL, Van Galen P, Pasieka JL, et al. An unusual tumor spectrum in Lynch syndrome caused by MSH6 mutation. Hereditary Cancer in Clinical Practice. 2010; 8: 17. Go to original source...
  13. Riff BP, Katona BW, Wilkerson M, et al. HNPCC‑associated pheochromocytoma: expanding the tumor spectrum. Pancreas 2014; 44: 676-678. Go to original source... Go to PubMed...
  14. Kaur RJ, Pichurin PN, Hines JM. Adrenal Cortical Carcinoma Associated With Lynch Syndrome: A Case Report and Review of Literature. Journal of the Endocrine Society, 2019; 3(4): 784-790. Go to original source... Go to PubMed...
  15. Benjamin G. Challis, Narayanan Kandasamy, Andrew S. Powlson, et al. Familial Adrenocortical Carcinoma in Association With Lynch Syndrome, J Clin Endocrinol Metab. 2016; 101(6): 2269-2272. Go to original source... Go to PubMed...
  16. Young WF. The incidentally discovered adrenal mass. Clinical practice. The New England journal of medicine, 2007; 356: 601-610. Go to original source... Go to PubMed...
  17. Čtvrtlík F, Tudos Z, Szász P, et al. Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. Biomedical Papers, 2019; 163 (3): 212-219. Go to original source... Go to PubMed...
  18. Balogova S, Talbot JN, Nataf V, et al. 18 F‑Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. European Journal of Nuclear Medicine and Molecular Imaging, 2013; 40: 943-966. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.